$0.00 EPS Expected for Forward Pharma A S (FWP); 4 Analysts Covering Pieris Pharmaceuticals (PIRS)

May 23, 2017 - By Vivian Currie

Among 4 analysts covering Pieris Pharmaceuticals (NASDAQ:PIRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pieris Pharmaceuticals had 7 analyst reports since July 22, 2015 according to SRatingsIntel. TH Capital initiated Pieris Pharmaceuticals Inc (NASDAQ:PIRS) on Wednesday, July 22 with “Buy” rating. Roth Capital reinitiated the stock with “Buy” rating in Friday, August 5 report. The firm earned “Outperform” rating on Tuesday, July 28 by Oppenheimer. JMP Securities initiated it with “Market Outperform” rating and $10 target in Wednesday, August 12 report. The firm has “Buy” rating given on Wednesday, July 22 by Roth Capital. On Thursday, August 13 the stock rating was maintained by Roth Capital with “Buy”. The stock of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. See Pieris Pharmaceuticals Inc (NASDAQ:PIRS) latest ratings:

Analysts expect Forward Pharma A S (NASDAQ:FWP) to report $0.00 EPS on June, 1. The stock decreased 0.71% or $0.14 on May 22, reaching $19.52. About shares traded. Forward Pharma A S (NASDAQ:FWP) has risen 4.69% since May 23, 2016 and is uptrending. It has underperformed by 12.01% the S&P500.

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $170.11 million. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. It currently has negative earnings. The Company’s Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

The stock decreased 2.72% or $0.11 on May 22, reaching $3.94. About shares traded. Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has risen 128.81% since May 23, 2016 and is uptrending. It has outperformed by 112.11% the S&P500.